There's a mix of positive and adverse impacts on Amgen's stock in the short term. The strong Q1 2007 results, impress with double-digit growth in several product franchises. However, the Vitex buque study's setback and the uncertainty aroundEpoch Indicus occurred in Q1, along with the muted 2007 revenue guidance, could cast a shadow over the stock's performance in the coming weeks. The злоотходств lack of clarity on the impact of recent developments onEpogen and Aranesp sales means investors might proceed with caution, leading to a Negative short-term impact. [-1]